Literature DB >> 24192901

Oral N(G)-nitro-L-arginine in conscious dogs: 24 hour hypertensive response in relation to plasma levels.

S Huber1, J G Grohs, S Schwarzacher, G Raberger.   

Abstract

Haemodynamic changes after oral administration of 30 mg/kg N(G)-nitro-L-arginine (L-NNA) were studied in conscious chronically instrumented mongrel dogs throughout a 24 h observation period in order to evaluate the long-term efficacy of L-NNA-induced inhibition of endothelium-dependent relaxation and its relation to plasma L-NNA level. Diastolic blood pressure remained elevated for the entire 24 h observation period, but systolic blood pressure was raised only up to the 6 h value. The hypertensive response was accompanied by bradycardia. The increase in blood pressure and the plasma L-NNA level both reached their maxima at 3 h. The plasma L-NNA level at the end of the observation period was diminished by only 21.7% with respect to the maximum increase, whilst the maximum increase in mean arterial blood pressure was attenuated by 72.2% at 24 h. These data show a dissociation between plasma L-NNA level and the respective blood pressure.

Entities:  

Year:  1992        PMID: 24192901     DOI: 10.1007/BF00805944

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  21 in total

1.  Differential selectivity of endothelium-derived relaxing factor and nitric oxide in smooth muscle.

Authors:  K Shikano; E H Ohlstein; B A Berkowitz
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

2.  L-NG-nitro arginine methyl ester exhibits antinociceptive activity in the mouse.

Authors:  P K Moore; A O Oluyomi; R C Babbedge; P Wallace; S L Hart
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

3.  Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase.

Authors:  R G Knowles; M Palacios; R M Palmer; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

5.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

6.  Nitric oxide modulates epicardial coronary basal vasomotor tone in awake dogs.

Authors:  A Chu; D E Chambers; C C Lin; W D Kuehl; F R Cobb
Journal:  Am J Physiol       Date:  1990-04

7.  NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide.

Authors:  R G Kilbourn; S S Gross; A Jubran; J Adams; O W Griffith; R Levi; R F Lodato
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Regional haemodynamic changes during oral ingestion of NG-monomethyl-L-arginine or NG-nitro-L-arginine methyl ester in conscious Brattleboro rats.

Authors:  S M Gardiner; A M Compton; T Bennett; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

9.  L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro.

Authors:  P K Moore; O A al-Swayeh; N W Chong; R A Evans; A Gibson
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

10.  L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation.

Authors:  R M Palmer; D D Rees; D S Ashton; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

View more
  1 in total

1.  Distribution and metabolism of NG-nitro-L-arginine and NG-nitro-L-arginine methylester in canine blood in vitro.

Authors:  K Krejcy; S Schwarzacher; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.